trametinib with TPX-0005 abolished the phosphorylation of STAT3 (Y705), paxillin (Y118), a readout of FAK, and Src (Y416). The median PFS of 32 KRAS mutant NSCLC p was 2.5 months and the overall survival was 13.4 months. According to CDCP1 levels, the median PFS was 3.5 months for those with low CDCP1 and 1.4 months for those with high CDCP1 (P = 0.012). The median survival was 16.3 months for p with low CDCP1, and only 3.2 months for those with high CDCP1 (P = 0.023). Conclusions: The combination of trametinib plus TPX-0005 shows significant in-vitro activity in the majority of KRAS mutant NSCLC cell lines and the mRNA levels of CDCP1 could be a biomarker in KRAS mutant NSCLC p, indicating the activation of Src-YAP signaling. Clinical trials with the combination of MEK inhibitors with TPX-0005 are warranted.
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Circulating microRNAs as novel predictive markers of afatinib efficacy in squamous cell lung cancer (SCC): An exploratory sub-analysis of the LUX-Lung 8 trial Background: Screening of circulating microRNAs is a promising avenue for the discovery of novel biomarkers in cancer therapy. In the LUX-Lung 8 trial, the ErbB family inhibitor Afatinib (A) provided a significant progression free survival (PFS) and overall survival (OS) benefit compared to the EGFR TKI Erlotinib (E) in 2nd line treatment of advanced SCC. To detect new markers associated with clinical outcomes, we performed a post hoc extensive screening of miRNAs in serum samples from a subset of LUX-Lung 8 trial patient population. Methods: 1787 miRNA expression levels were measured by miRNA-seq using the Illumina HiSeq4000 platform in baseline (BL) (n = 133) and cycle 2 (C2) (n = 109) serum samples from 133 LUX-Lung 8 patients randomly selected with stratification on smoking, treatment, and interval from last dose of chemotherapy. All variables were tested for their BL prognostic and predictive value on OS in a Cox model adjusted for prognostic factors. For miRNAs with FDR adjusted p-value <0.05, a data-driven cut-off was determined and Kaplan Meier estimates were performed comparing low-and high-expressers. Analysis of C2 values was conducted. Results: 29 miRNAs were found to be prognostic of OS and 8 to be predictive of treatment effect on OS with FDR p-value p < 0.05. MiR-3150b-3p was the most significant predictive variable (FDR p < 0.001). In the A arm, median OS was 2.7 m in miR-3150b-3p high-vs 8.5 m in lowexpressers (HR = 3.4, p = 0.0001) and 5.7 m in highexpressers treated with E (HR = 2.7, p = 0.01). Furthermore, in the A arm, but not in the E arm, high miR-3150b-3p expression at C2 in patients with low BL values was associated with a shorter OS compared to patients remaining low (7.4 m vs 10.4 m, HR = 2; p = 0.08). Conclusions: Using a rigorous methodology, we found new highly prognostic markers and several novel markers with high predictive value of a differential treatment benefit between A and E. This suggests the two drugs have different mechanism of action. Because this was an exploratory analysis and the effect size could be over-estimated, those results should be replicated in a larger study. Clinical trial identification: NCT01523587 Legal entity responsible for the study: IntegraGen Background: MicroRNA miR-31-3p and 5p have been reported to predict anti-EGFR cetuximab efficacy in metastatic colorectal cancer but have not been studied in other indications. In the LUX-Lung 8 trial, ErbB family blocker Afatinib (A) provided a significant PFS and OS benefit compared to EGFR TKI Erlotinib (E) in 2nd line treatment of advanced SCC. We retrospectively analyzed the association of miR-31-3p and miR-31-5p serum levels with treatment benefit in a sub-population of this study. Methods: MiRNA expression levels from baseline (BL) (n = 133) and cycle 2 (C2) (n = 109) serum samples from 133 LUX-Lung 8 trial patients selected randomly with stratification on smoking status, treatment and interval from last dose of chemotherapy were measured by miRNA-Seq using Illumina HiSeq4000 platform. MiR-31-3p, miR-31-5p or combined miR-31 were tested for their prognostic and predictive value of treatment effect on OS using Cox models adjusted for prognostic factors and Kaplan Meier estimates after determination of a data-driven cut-off defining low or high expressers. Conclusions: MiR-31-3p/5p serum levels were predictive of E treatment efficacy. Patients with high BL miR-31 levels had lower benefit of E and higher benefit of A, suggesting different mechanisms of action for the drugs. Increase of miR-31 levels during treatment with E was associated with poor outcomes. Measurement of circulating mir-31 has potential to help optimizing treatment choice between E and A for SCC patients. Those results should be replicated in a larger study. Clinical trial identification: NCT01523587 Legal entity responsible for the study: IntegraGen Funding: IntegraGen Disclosure: Y. Gaston Mathe: Employee of IntegraGen, the sponsor of the study and owner of IP rights on the disclosed results. P. Fogel: Fees from the study sponsor for the performance of the statistical analysis. S. Martin-Lannereé, C. Marcaillou, E. Lallet: Employee of the study sponsor. Background: Epidemiologic data have indicated that chronic inflammation was highly associated with the pathogenesis of lung cancer. However, the molecular relations between inflammation and lung cancer have not been well understood. MicroRNAs could connect the inflammatory response with tumorigenesis through regulating their cancer-related targets. The aim of the present study was to identify the core miRNA in inflammationrelated lung cancer and its potential mechanisms. Methods: RT-PCR was used to detect the expression of miRNAs and mRNAs. CKK8 and flow cytometry assays was performed for the function experiments. Microarray analysis and IPA analysis were used to predict the potential signal pathway. Results: Mir-125b was the most dramatically up-regulated miRNAs after treated with IFN-r, whereas after stimulated with IL-10, mir-125b was the most strikingly down-regulated ones. Restoration of mir-125b expression could completely overrode the impact of IL-10 on both cell proliferation and apoptosis in NSCLC cell lines. And the level of mir-125b was significantly lower in 30 NSCLC tumor tissues compared with normal controls (P < 0.0001). Microarray analysis found 69 up-regulated genes and 105 down-regulated genes after down-regulate mir-125b. And IPA analysis indicated that IGF-1 signaling pathway was dramatically activated. The results were validated by RT-PCR. Conclusions: MiR-125b might play a tumor suppressor role via inhibiting IGF-1 signaling in inflammation-related lung cancer. Legal entity responsible for the study: Yanwei Zhang Funding: Has not received any funding Disclosure: All authors have declared no conflicts of interest.
